UroGen Pharma Overview
UroGen Pharma (URGN) has a ROE of 73.75%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow73.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, URGN shows a ROE of 73.75%. That is above the Healthcare sector average of 20.86%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 20.86%. UroGen Pharma is at 73.75%, which is higher that average. That is roughly 253.6% above the sector mean. Use the comparison chart on this page to see how URGN stacks up against individual peers as well.
Check the historical chart to see whether URGN's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare UroGen Pharma with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has UroGen Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 73.75%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 20.86%, while URGN is at 73.75%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
